共 26 条
[1]
Blick S.K., Scott L.J., Cetuximab: A review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer, Drugs, 67, pp. 2585-2607, (2007)
[2]
Erbitux (Package Insert), (2013)
[3]
Cunningham D., Humblet Y., Siena S., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med, 351, pp. 337-345, (2004)
[4]
Bonner J.A., Harari P.M., Giralt J., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med, 354, pp. 567-578, (2006)
[5]
Bonomi P.D., Mace J., Mandanas R.A., Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with Stage IIIB/IV non-small-cell lung cancer, J Thorac Oncol, 8, pp. 338-345, (2013)
[6]
Carey L.A., Rugo H.S., Marcom P.K., TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer, J Clin Oncol, 30, pp. 2615-2623, (2012)
[7]
Asnacios A., Fartoux L., Romano O., Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: Results of a multicenter phase 2 study, Cancer, 112, pp. 2733-2739, (2008)
[8]
Foley K.A., Wang P.F., Barber B.L., Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab, Ann Oncol, 21, pp. 1455-1461, (2010)
[9]
Siena S., Glynne-Jones R., Adenis A., Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication, Cancer, 116, pp. 1827-1837, (2010)
[10]
Sobrero A.F., Maurel J., Fehrenbacher L., EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer, J Clin Oncol, 26, pp. 2311-2319, (2008)